Mingxi is the President of Apeiron Therapeutics. Dr. Li specializes in identifying and commercializing early-stage life science innovation. He started his career at Jiuding Capital, focusing on healthcare investments in China and led the investment in Zhejiang Chengyi Pharmaceutical (SH: 603811). Mingxi later joined Simcere Pharmaceutical Group managing its $US 200 million investment in life […]
Fred Aswad is Apeiron Therapeutics’ vice president of biology. Dr. Aswad has nearly 15 years of research and development experience in the biotechnology industry. He began his career at Bayer, where he played a leadership role in developing the immuno-oncology portfolio and development of novel drug discovery platforms. After Bayer, he went on to become […]
Dr. Gu is Apeiron Therapeutics’ Vice President of Research and Head of Chemistry. Dr. Gu has over 20 years research and development experience in the pharmaceutical industry. Dr. Gu has been engaged in the research, development and management of novel drugs at several pharmaceutical companies and CROs, including X-Ceptor, Exelixis, ShangPharma, Otsuka and Pharmaron. Prior […]
Dr.Joseph is the Senior Director of Biology at Apeiron Therapeutics. He has over fifteen years of small molecule oncology drug discovery experience leading research teams supporting preclinical activities ranging from new target identification and validation to translational biology supporting ongoing clinical trials. Most recently Jim was an Associate Director at Ideaya Biosciences where he led […]
Dr. Wang is Apeiron Therapeutics’ Director of biology. Dr. Wang has more than 8 years of research and development experience in the Pharmaceutical industry. He began his career at Shanghai Medicilon Inc, where he focused on developing drug discovery platforms including drug discovery based on FBDD/SBDD and biophysical methods. At Shanghai Medicilon, as the Director […]
Qiushi is head of project management at Apeiron Therapeutics. Qiushi has been responsible for leading project management efforts of several preclinical and clinical development programs. Prior to joining GT Apeiron, he was responsible for R&D project management at the Yangtze River Pharmaceutical Group.